[
  {
    "ts": null,
    "headline": "Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal",
    "summary": "Novavax (NVAX) is back in focus after Q4 2025 results showed surprise profitability, with revenue of US$147.14 million and net income of US$17.53 million, supported by key vaccine partnerships and milestone payments. See our latest analysis for Novavax. The latest earnings surprise has come after a sharp move in the share price, with a 1 day share price return of a 9.38% decline following a strong 90 day share price return of 43.83% and a 1 year total shareholder return of 21.73%. However,...",
    "url": "https://finnhub.io/api/news?id=5eb16a852ae59f540b40d9116483d618a5694f65d64b36245611a71b1f665455",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772291538,
      "headline": "Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal",
      "id": 139264504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax (NVAX) is back in focus after Q4 2025 results showed surprise profitability, with revenue of US$147.14 million and net income of US$17.53 million, supported by key vaccine partnerships and milestone payments. See our latest analysis for Novavax. The latest earnings surprise has come after a sharp move in the share price, with a 1 day share price return of a 9.38% decline following a strong 90 day share price return of 43.83% and a 1 year total shareholder return of 21.73%. However,...",
      "url": "https://finnhub.io/api/news?id=5eb16a852ae59f540b40d9116483d618a5694f65d64b36245611a71b1f665455"
    }
  }
]